New and More Dangerous Cholesterol Found In Your Blood (Lipoprotein(a) - LPa)
Talking With Docs・12 minutes read
LP little a is a harmful molecule linked to heart issues and stroke, with around 20% of people in North America and Europe having high levels. Genetic and unaffected by lifestyle changes, clinical trials are ongoing to develop drugs that can lower LP little a levels by 50-60%.
Insights
- LP little a, a molecule similar to LDL but more harmful, is genetically determined, not influenced by diet or exercise, and linked to increased risks of heart attack, stroke, and heart failure.
- Clinical trials are exploring drug options to reduce LP little a levels by 50-60%, highlighting the importance of regular testing and potential lifestyle changes to manage the associated health risks effectively.
Get key ideas from YouTube videos. It’s free
Recent questions
What is LP little a?
LP little a is a harmful molecule similar to LDL but with additional inflammatory, clotting, and atherogenic properties.
How can LP little a levels be lowered?
PCSK9 Inhibitors can reduce LP little a by 30-40%.
What are the risks associated with elevated LP little a levels?
Elevated LP little a is linked to higher risks of heart attack, aortic stenosis, stroke, and heart failure.
Can lifestyle changes impact LP little a levels?
Lifestyle changes like maintaining a healthy weight, quitting smoking, and regular exercise can help manage the risks associated with elevated LP little a levels.
Are there medications available to lower LP little a levels?
PCSK9 Inhibitors can reduce LP little a by 30-40%, but there are ongoing clinical trials to develop drugs that can lower LP little a levels by 50-60%.
Related videos
Peter Attia MD
What genes are associated with longevity? | Peter Attia & Nir Barzilai
The Minimalists
Don’t Worry About “Bad” Cholesterol, Says Dr. Paul Saladino
ABC News (Australia)
World's largest study in COVID vaccine side-effects | ABC News
prema anandan
Anti hyperlipidemic agents 1 | Medicinal Chemistry | III B Pharm V Semester - Unit 3 | III Pharm D
Dr. Pradip Jamnadas, MD
Evolution of Cardiac Diagnostics: A New Era with AI-Powered FFR-CT
Summary
00:00
LP little a: Genetic molecule linked to heart risks
- LP little a is a molecule similar to LDL but with additional harmful features like inflammation, clotting promotion, and atherogenic properties.
- LP little a is associated with increased risks of heart attack, aortic stenosis, stroke, and heart failure.
- LP little a levels vary globally, with around 20% of the population in North America and Europe having higher values.
- LP little a is genetic, not influenced by diet or exercise, and currently lacks medications for lowering it.
- Clinical trials are ongoing to develop drugs that can reduce LP little a levels by 50-60%.
- Elevated LP little a indicates higher risk, prompting lifestyle changes like maintaining a healthy weight, quitting smoking, and regular exercise.
- Lowering LDL levels does not directly impact LP little a, but PCSK9 Inhibitors, a class of medications, can reduce LP little a by 30-40%.
- The impact of lowering LP little a on reducing cardiovascular risks is still under study, with ongoing clinical trials to determine its effectiveness.
- Regular testing for LP little a is recommended, especially for those at higher risk, to monitor and manage potential health risks associated with elevated levels.
